Novo Nordisk, obesity and Weight-Loss Drug
Novo Nordisk reported results on its next-generation obesity drug in diabetes patients, including data on weight loss that ...
Novo Nordisk stock tumbled Monday morning after disappointing trial results for its CagriSema weight-loss drug. Shares in ...
Novo Nordisk (NVO), the company behind popular diabetes and obesity treatments Ozempic and Wegovy, saw its stock rise on Thursday after ...
Novo Nordisk will start selling its obesity drug Wegovy directly to patients at a reduced price, following a similar move ...
AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.
4d
Verywell Health on MSNNovo Nordisk Offers Wegovy for $499 a Month in Direct-to-Consumer ProgramNovo Nordisk announced a direct-to-consumer program that allows patients to buy Wegovy out of pocket at a lower cost.
Proficio Capital Partners LLC acquired a new stake in shares of Novo Nordisk A/S (NYSE:NVO – Free Report) in the 4th quarter, ...
Get key updates on stock ratings this week, from Intel's leadership-driven upgrade to Apple's tariff challenges.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results